Your session is about to expire
What is Viroptic
TrifluridineThe Generic name of this drug
Treatment SummaryTrifluridine is a medication used to treat common eye infections caused by the herpes simplex virus. It is also used in combination with another drug, tipiracil, to treat metastatic colorectal cancer in adults. This drug works by preventing the replication of cancer cells and incorporating into the DNA of cancer cells.
Viropticis the brand name
Viroptic Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Viroptic
Trifluridine
1980
7
Approved as Treatment by the FDA
Trifluridine, commonly known as Viroptic, is approved by the FDA for 4 uses which include previously treated with anti-VEGF and RAS wild-type with previous of anti-EGFR therapy .previously treated with anti-VEGF
Used to treat previously treated with anti-VEGF in combination with Tipiracil
RAS wild-type with previous of anti-EGFR therapy
Used to treat RAS wild-type with previous of anti-EGFR therapy in combination with Tipiracil
oxaliplatin
Used to treat previous treatment with fluoropyrimidine, oxaliplatin and irinotecan in combination with Tipiracil
Colorectal Cancer
Used to treat Metastatic Colorectal Cancer (CRC) in combination with Tipiracil
Effectiveness
How Viroptic Affects PatientsTrifluridine is a drug used to treat herpes simplex virus, adenovirus, and vacciniavirus. It has also been used to treat dendritic ulcers in those who are not responding to other treatments. In laboratory studies, it has been found to be effective against both common and resistant types of colorectal cancer. When administered to patients with advanced solid tumors, it was found to not have any significant effects on prolonging the heart's QT/QTc interval.
How Viroptic works in the bodyTrifluridine works to stop viral replication and inhibit cancer cell growth. It does this by being incorporated into viral DNA, causing defective proteins and a higher mutation rate. Trifluridine is also incorporated into the DNA of tumor cells, disrupting how the cells use DNA and how they reproduce. In tumor cells, trifluridine also inhibits an enzyme involved in DNA synthesis. This makes it harder for tumor cells to resist antineoplastic therapies.
When to interrupt dosage
The proposed dosage of Viroptic is contingent upon the diagnosed condition, including Pharmacotherapy, prophylaxis of vaccinia contamination in the cornea and conjunctiva and Eyelid anatomy. The amount of dosage is dependent upon the method of administration (e.g. Tablet - Oral or Oral) outlined in the table beneath.Condition
Dosage
Administration
prophylaxis of vaccinia infection in the cornea and conjunctiva
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
smallpox vaccinations
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Communicable Diseases
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Eyelid structure
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
herpesvirus 2, human
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
vaccinia infection in the cornea and conjunctiva
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Herpes Simplex Infections
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Blepharitis
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
disease progression after 2 or more HER2/neu-targeted therapy
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
oxaliplatin
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Metastatic Gastric Adenocarcinoma
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Metastatic Gastroesophageal Junction Adenocarcinoma
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
at least two prior systemic chemotherapy regimens
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
RAS wild-type with previous of anti-EGFR therapy
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
previously treated with anti-VEGF
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Pharmacotherapy
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Colorectal Cancer
, 10.0 mg/mL, 1.0 %, 20.0 mg, 15.0 mg
Ophthalmic, , Solution, Solution - Ophthalmic, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, Tablet - Oral
Warnings
There are 20 known major drug interactions with Viroptic.Common Viroptic Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Trifluridine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Trifluridine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Trifluridine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Trifluridine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Trifluridine is combined with Acteoside.
Viroptic Toxicity & Overdose RiskThe toxic dose of Lonsurf in rats is 2946mg/kg and greater than 4379mg/kg in rats and mice, respectively. It is unlikely that an overdose can occur through eye drops. The highest dose of Lonsurf taken orally in clinical studies was 180mg/m^2 per day. An overdose may lead to decreased production of blood cells and there is currently no antidote available. Pregnant patients should be aware that animal studies have shown trifluridine to cause fetal toxicity.
Viroptic Novel Uses: Which Conditions Have a Clinical Trial Featuring Viroptic?
49 active clinical trials are currently being conducted to assess the potential of Viroptic for Pharmacotherapy, the prophylaxis of vaccinia infection in the cornea and conjunctiva, and the treatment of Communicable Diseases.Condition
Clinical Trials
Trial Phases
Colorectal Cancer
46 Actively Recruiting
Phase 3, Phase 2, Phase 1, Not Applicable
Blepharitis
0 Actively Recruiting
vaccinia infection in the cornea and conjunctiva
0 Actively Recruiting
RAS wild-type with previous of anti-EGFR therapy
0 Actively Recruiting
oxaliplatin
0 Actively Recruiting
Metastatic Gastroesophageal Junction Adenocarcinoma
19 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Early Phase 1, Phase 3
herpesvirus 2, human
0 Actively Recruiting
previously treated with anti-VEGF
0 Actively Recruiting
prophylaxis of vaccinia infection in the cornea and conjunctiva
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
smallpox vaccinations
0 Actively Recruiting
disease progression after 2 or more HER2/neu-targeted therapy
0 Actively Recruiting
at least two prior systemic chemotherapy regimens
0 Actively Recruiting
Eyelid structure
0 Actively Recruiting
Herpes Simplex Infections
0 Actively Recruiting
Metastatic Gastric Adenocarcinoma
9 Actively Recruiting
Phase 2, Phase 1, Phase 3, Early Phase 1
Pharmacotherapy
0 Actively Recruiting
Viroptic Reviews: What are patients saying about Viroptic?
5Patient Review
3/22/2012 I've been using this treatment since my first outbreak in 1983 and it's always worked really well for me. I'm hoping it will still be effective now that I have cataract implants.
3.7Patient Review
1/16/2010 The pain was excruciating, and the light sensitivity made it impossible to function. I've never been this sick in my life.
2Patient Review
5/11/20091Patient Review
7/1/2009Patient Q&A Section about viroptic
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Trifluridine a steroid?
"Trifluridine is an antiviral medication used to treat infections caused by certain viruses. It is taken as a solution or eye drops and is applied to the affected area."
Answered by AI
How do you get prescribed Viroptic?
"is the most recent update for this text. The recommended dosage for VIROPTIC Ophthalmic Solution, 1% is one drop onto the cornea of the affected eye every 2 hours while awake, for a maximum of 9 drops per day. This is until the corneal ulcer has completely re-epithelialized."
Answered by AI
What is Viroptic used for?
"Trifluridine is used to treat certain types of eye infections that are caused by the herpes type 1 or 2 virus. These infections include primary keratoconjunctivitis and epithelial keratitis, which cause inflammation of the eye tissues at the front of the eye. Trifluridine can help to prevent these infections from recurring."
Answered by AI
What are the side effects of Trifluridine?
"If you experience any of the following after using this medication, contact your doctor immediately: blurred vision, changes in vision, dryness of the eye, irritation of the eye, itching, redness, swelling, or any other sign of irritation."
Answered by AI